Sargramostim · Leukine

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Acute Myeloid Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (3)
US
  • LEUKINE is a leukocyte growth factor indicated: to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML); for the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation in adult patients; for the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation in adult and pediatric patients 2 years of age and older; for the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older; for treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older; to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).
  • Acute Exposure to Myelosuppressive Doses of Radiation (H-ARS) LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).
Product first approved 1991Outside this platform's coverageFDA label
EU
  • Imreplys is indicated for treatment of patients of all ages acutely exposed to myelosuppressive doses of radiation with Haematopoietic Sub-syndrome of Acute Radiation Syndrome (H-ARS). Imreplys should be used in accordance with official radiological/nuclear emergency recommendations.
Product first approved 2025Outside this platform's coverageEMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (40)
Acute Myeloid Leukemia
NCT04229979 · Sellas Life Sciences Group
2021-02-08 – 2026-12 · Acute Myeloid Leukemia
What this study did
NCT00049517 · Eastern Cooperative Oncology Group
2002-12-19 – 2019-12 · Leukemia
What this study did
NCT01324063 · European Organisation for Research and Treatment of Cancer - EORTC
1986-11 – 1994-06 · Leukemia
What this study did
Other / comorbidity
NCT05232916 · Greenwich LifeSciences, Inc.
2022-12-16 – 2031-12 · Breast Cancer
What this study did
NCT03126916 · Children's Oncology Group
2018-05-14 – 2030-09-30 · Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
What this study did
NCT00026312 · National Cancer Institute (NCI)
2001-10-26 – 2025-12-31 · Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
What this study did
NCT05266001 · Nationwide Children's Hospital
2022-06-14 – 2025-09-10 · Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
What this study did
NCT01041638 · National Cancer Institute (NCI)
2009-12-21 – 2021-06-30 · High Risk Neuroblastoma
What this study did
NCT02361528 · Hospices Civils de Lyon
2015-09-14 – 2018-06-01 · Septic Shock, Severe Sepsis
What this study did
NCT01826864 · Jonsson Comprehensive Cancer Center
2011-08-05 – 2017-08-08 · Stage IB Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma
What this study did
NCT01480479 · Celldex Therapeutics
2011-11 – 2016-11 · Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
What this study did
NCT01875653 · Lisata Therapeutics, Inc.
2014-10 – 2016-01 · Stage IV Melanoma, Stage III Melanoma
What this study did
NCT00050531 · M.D. Anderson Cancer Center
2003-04 – 2015-08 · Leukemia, Myeloid, Chronic
What this study did
NCT01265901 · Immatics Biotechnologies GmbH
2010-12 – 2015-07 · Metastatic Renal Cell Carcinoma
What this study did
NCT00083551 · University of Arkansas
1998-08 – 2014-08 · Multiple Myeloma
What this study did
NCT00002599 · Medical Research Council
started 1994-09 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00425360 · Royal Liverpool University Hospital
2006-09 – 2013-03 · Pancreatic Cancer
What this study did
NCT01989572 · National Cancer Institute (NCI)
2000-02-23 – 2013-01-31 · Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Melanoma, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IIA Cutaneous Melanoma AJCC v6 and v7, Stage IIA Uveal Melanoma AJCC v7, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIB Uveal Melanoma AJCC v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
What this study did
NCT00002766 · Memorial Sloan Kettering Cancer Center
1996-03 – 2011-09 · Leukemia, Lymphoma
What this study did
NCT00002995 · Children's Oncology Group
1997-08 – 2011-01 · Sarcoma
What this study did
NCT00003093 · Children's Oncology Group
1988-03 – 2011-01 · Neuroblastoma
What this study did
NCT00293462 · Marilyn Dodd
2005-06-07 – 2009-12-31 · Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
What this study did
NCT00003958 · Children's Oncology Group
2002-09 – 2007-10 · Adult Malignant Mesenchymoma, Adult Rhabdomyosarcoma, Alveolar Childhood Rhabdomyosarcoma, Childhood Malignant Mesenchymoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Previously Untreated Childhood Rhabdomyosarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma
What this study did
NCT00002514 · Eastern Cooperative Oncology Group
1993-05-07 – 2006-12 · Leukemia
What this study did
NCT00295165 · Genzyme, a Sanofi Company
2006-01 – 2006-10 · Crohn Disease
What this study did
NCT00206713 · Genzyme, a Sanofi Company
2004-07 – 2006-10 · Crohn Disease
What this study did
NCT00206674 · Genzyme, a Sanofi Company
2004-09 – 2006-06 · Crohn Disease
What this study did
NCT00237575 · University of Kentucky
2005-11 – 2006-03 · Bladder Cancer
What this study did
NCT00003119 · Children's Oncology Group
1998-03 – 2006-03 · Neuroblastoma
What this study did
NCT00002070 · Schering-Plough
— · Cytomegalovirus Retinitis, HIV Infections
What this study did
NCT00008398 · Radiation Therapy Oncology Group
2000-10 – 2004-03 · Head and Neck Cancer, Oral Complications, Radiation Toxicity
What this study did
NCT00003972 · Fred Hutchinson Cancer Center
1998-07 – 2003-03 · Breast Cancer
What this study did
NCT04446052 · Eastern Cooperative Oncology Group
1993-05-21 – 2002-07-10 · Adult Patients (Over 55) With Acute Non-Lymphocytic Leukemia
What this study did
NCT00001338 · National Cancer Institute (NCI)
1993-06 – 2001-01 · Breast Neoplasms, Fever, Hematologic Diseases, Neutropenia, Sepsis
What this study did
NCT00003315 · Medical Research Council
1997-07 – 1997-12 · Infection
What this study did
NCT00000658 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 1996-02 · Lymphoma, Non-Hodgkin, HIV Infections
What this study did
Phase 2/3 (3)
Acute Myeloid Leukemia
NCT00630565 · Masonic Cancer Center, University of Minnesota
2006-07-26 – 2022-07-28 · Leukemia
What this study did
Other / comorbidity
NCT02339571 · National Cancer Institute (NCI)
2015-11-23 – 2033-06-30 · Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
What this study did
NCT04642950 · Nobelpharma
2020-12-17 – 2021-10-25 · COVID-19
What this study did
Phase 2 (254)
Acute Myeloid Leukemia
NCT02593123 · Virginia Commonwealth University
2015-11-04 – 2022-03-18 · Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma, Leukemia, Myeloma, Acute Lymphocytic Leukemia, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Recurrent Acute Myeloid Leukemia, Adult, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
What this study did
NCT01700673 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2013-06 – 2020-06 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT02520102 · Sanofi
2017-02 – 2017-02-28 · Acute Myeloid Leukemia NOS
What this study did
NCT01158118 · Washington University School of Medicine
2011-04-01 – 2016-12-31 · Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphoma, Non-Hodgkin, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Multiple Myeloma
What this study did
NCT00425477 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2006-11 – 2016-09-30 · Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
What this study did
NCT01266083 · Sellas Life Sciences Group
2011-01-14 – 2016-09-30 · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
What this study did
NCT00462605 · National Cancer Institute (NCI)
2007-04 – 2011-03 · Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
What this study did
NCT00488592 · National Heart, Lung, and Blood Institute (NHLBI)
2007-06 – 2010-04 · Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)
What this study did
NCT00066794 · SWOG Cancer Research Network
2004-07 – 2010-01 · Leukemia
What this study did
NCT00023777 · SWOG Cancer Research Network
2001-08 – 2008-04 · Leukemia
What this study did
NCT00005962 · Eastern Cooperative Oncology Group
2000-10-04 – 2007-06 · Leukemia
What this study did
NCT00533923 · Beth Israel Deaconess Medical Center
2002-12 – 2007-01 · AML, ALL, CLL, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Aplastic Anemia, Myeloproliferative Disorder
What this study did
NCT00004217 · SWOG Cancer Research Network
2000-02 – 2006-03 · Leukemia
What this study did
NCT00006240 · National Heart, Lung, and Blood Institute (NHLBI)
2000-10 – 2001-08 · Leukemia
What this study did
Other / comorbidity
NCT06450041 · New Approaches to Neuroblastoma Therapy Consortium
2024-12-16 – 2038-12 · Neuroblastoma
What this study did
NCT07949760 · University of Washington
2026-11-30 – 2035-12-31 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Metastatic Hormone Receptor-Negative Breast Carcinoma
What this study did
NCT07169617 · National Cancer Institute (NCI)
2026-10-01 – 2029-12-31 · Lung Carcinoma
What this study did
NCT06528496 · Memorial Sloan Kettering Cancer Center
2024-07-22 – 2029-07-22 · High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma
What this study did
NCT03794349 · Children's Oncology Group
2019-07-08 – 2029-03-31 · High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
What this study did
NCT07085338 · St. Jude Children's Research Hospital
2025-11-10 – 2029-02-01 · Neuroblastoma Recurrent
What this study did
NCT06202066 · Roswell Park Cancer Institute
2026-12-15 – 2028-12-15 · Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm, Pancreatic Neuroendocrine Neoplasm
What this study did
NCT03630211 · Paul Szabolcs
2018-07-31 – 2028-08-01 · Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
What this study did
NCT05455658 · University of Washington
2022-11-17 – 2028-07-16 · Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
What this study did
NCT07078604 · University of Washington
2026-03-24 – 2028-06-30 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
What this study did
NCT03363373 · Y-mAbs Therapeutics
2018-04-03 – 2028-04 · Neuroblastoma
What this study did
NCT04237623 · Northside Hospital, Inc.
2020-05-18 – 2027-12-31 · Transplant-Related Hematologic Malignancy
What this study did
NCT03600350 · University of Wisconsin, Madison
2018-09-10 – 2027-12 · Prostate Cancer
What this study did
NCT04385277 · Children's Oncology Group
2020-12-31 – 2027-09-30 · Ganglioneuroblastoma, Nodular, Neuroblastoma
What this study did
NCT05344209 · Vestre Viken Hospital Trust
2022-08-12 – 2027-07-01 · Oncology, NSCLC Stage IV, NSCLC, Stage III
What this study did
NCT02502786 · Memorial Sloan Kettering Cancer Center
2015-07 – 2027-07 · Recurrent Osteosarcoma
What this study did
NCT04936529 · Memorial Sloan Kettering Cancer Center
2021-08-02 – 2027-06-15 · Neuroblastoma
What this study did
NCT01134614 · National Cancer Institute (NCI)
2010-12-28 – 2027-03-19 · Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
What this study did
NCT04300244 · Åslaug Helland
2020-05-04 – 2027-03-15 · Cancer, Cancer, Lung, Cancer of Lung, Mesothelioma, Mesothelioma; Lung, Mesothelioma; Pleura, Mesotheliomas Pleural
What this study did
NCT02455557 · Roswell Park Cancer Institute
2015-05-04 – 2026-12-02 · Glioblastoma, Gliosarcoma
What this study did
NCT04902703 · University of Colorado, Denver
2022-06-01 – 2026-11-30 · Alzheimer Disease
What this study did
NCT04739618 · ImmunSYS, LLC
2021-03-04 – 2026-11-10 · Metastatic Cancer
What this study did
NCT05482334 · University of Colorado, Denver
2023-10-23 – 2026-09 · Down Syndrome
What this study did
NCT01903330 · Epitopoietic Research Corporation
2014-03 – 2026-06 · Glioblastoma, Gliosarcoma
What this study did
NCT03786783 · National Cancer Institute (NCI)
2019-03-04 – 2026-03-31 · Ganglioneuroblastoma, High Risk Neuroblastoma
What this study did
NCT01391962 · National Cancer Institute (NCI)
2011-07-18 – 2026-01-16 · Sarcoma, Alveolar Soft Part
What this study did
NCT01857934 · St. Jude Children's Research Hospital
2013-07-05 – 2025-12-31 · Neuroblastoma
What this study did
NCT03033303 · Memorial Sloan Kettering Cancer Center
2017-01-23 – 2025-09-29 · Neuroblastoma
What this study did
NCT05284214 · Partner Therapeutics, Inc.
2024-01 – 2025-09 · Solid Tumor, Solid Tumor, Adult
What this study did
NCT00799110 · Beth Israel Deaconess Medical Center
2008-05 – 2025-09 · Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
What this study did
NCT03304821 · Emory University
2017-12-19 – 2025-07-05 · Peripheral Artery Disease (PAD)
What this study did
NCT04703426 · Dana-Farber Cancer Institute
2021-04-16 – 2025-06-09 · Unresectable Melanoma, Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
What this study did
NCT03376477 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-09-23 – 2025-05-30 · Multiple Myeloma
What this study did
NCT05075122 · Martin-Luther-Universität Halle-Wittenberg
2021-08-02 – 2025-02 · Head and Neck Squamous Cell Carcinoma
What this study did
Phase 1/2 (43)
Acute Myeloid Leukemia
NCT03761914 · Sellas Life Sciences Group
2019-09-30 – 2022-10-27 · Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
What this study did
NCT00004918 · National Cancer Institute (NCI)
1999-12 – 2007-12 · Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia
What this study did
Other / comorbidity
NCT05101356 · University of California, Davis
2021-01-13 – 2034-01-01 · Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Adenocarcinoma, Recurrent Malignant Solid Neoplasm
What this study did
NCT06626516 · Thomas Jefferson University
2025-10-15 – 2032-08 · Metastatic Uveal Melanoma
What this study did
NCT07437963 · National Cancer Institute (NCI)
2027-06-25 – 2029-09-30 · Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
What this study did
NCT05269381 · Mayo Clinic
2022-03-31 – 2028-03-31 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Cervical Carcinoma, Locally Advanced Endometrial Carcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Locally Advanced Merkel Cell Carcinoma, Locally Advanced Renal Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Locally Advanced Unresectable Cervical Carcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Unresectable Renal Cell Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Skin Squamous Cell Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Cervical Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hepatocellular Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Renal Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma, Breast Adenocarcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Invasive Breast Lobular Carcinoma
What this study did
NCT04211675 · Nationwide Children's Hospital
2022-09-01 – 2027-12 · Relapsed Neuroblastoma, Refractory Neuroblastoma
What this study did
NCT01757626 · Memorial Sloan Kettering Cancer Center
2012-12 – 2026-12 · Neuroblastoma
What this study did
NCT04238819 · Eli Lilly and Company
2020-11-09 – 2025-08-19 · Relapsed Solid Tumor, Refractory Solid Tumor
What this study did
NCT00458536 · Beth Israel Deaconess Medical Center
2004-10 – 2023-07 · Renal Cancer
What this study did
NCT02620865 · Barbara Ann Karmanos Cancer Institute
2015-12 – 2021-06-21 · Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
What this study did
NCT02275416 · Ultimovacs ASA
2015-02-02 – 2020-11-03 · Malignant Melanoma
What this study did
NCT01784913 · Ultimovacs ASA
2013-04-15 – 2020-10-23 · Prostate Cancer
What this study did
NCT01789099 · Ultimovacs ASA
2013-04-08 – 2020-06-12 · Non-small Cell Lung Cancer
What this study did
NCT02173093 · University of Virginia
2014-11 – 2019-12 · Disseminated Neuroblastoma, Recurrent Neuroblastoma
What this study did
NCT03282188 · University of Leeds
2017-10 – 2018-07 · Melanoma, Cancer of Skin
What this study did
NCT00088413 · National Cancer Institute (NCI)
2004-07-21 – 2018-05-31 · Adenocarcinoma, Colorectal Cancer, Ovarian Cancer, Breast Cancer
What this study did
NCT02078648 · Stemline Therapeutics, Inc.
2014-05 – 2018-01-22 · Adult Brain Glioblastoma, Glioblastoma Multiforme
What this study did
NCT01827137 · Sellas Life Sciences Group
2013-04 – 2017-11-06 · Multiple Myeloma
What this study did
NCT02009397 · University of Louisville
2012-02 – 2016-11 · Metastatic Melanoma
What this study did
NCT01580696 · COL George Peoples, MD, FACS
2012-04 – 2016-07-31 · Ovarian Cancer, Endometrial Cancer, Fallopian Cancer, Peritoneal Cancer
What this study did
NCT01653665 · Newcastle-upon-Tyne Hospitals NHS Trust
2012-08 – 2015-02 · Critical Illness, Sepsis, Immuno-suppression
What this study did
NCT00791037 · University of Washington
2008-10 – 2014-12 · HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
What this study did
NCT01592045 · United Therapeutics
2012-08 – 2014-06 · Neuroblastoma
What this study did
NCT00546377 · Memorial Sloan Kettering Cancer Center
2005-07 – 2014-05 · Leukemia, Lymphoma
What this study did
NCT00002817 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
started 1996-04 · Melanoma (Skin)
What this study did
NCT00002780 · St. Luke's Medical Center
started 1996-05 · Breast Cancer
What this study did
NCT01627678 · Bionor Immuno AS
2012-09 – 2013-11 · HIV-1 Infection
What this study did
NCT01355393 · University of Washington
2011-07 – 2013-11 · HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT00939510 · Robert Dreicer MD
2005-07 – 2012-12 · Prostate Cancer
What this study did
NCT00093548 · Jonsson Comprehensive Cancer Center
— · Liver Cancer
What this study did
NCT00048893 · National Cancer Institute (NCI)
2002-11 – 2011-06 · Breast Neoplasms, Metastases, Neoplasm
What this study did
NCT00602706 · Mayo Clinic
2000-01 – 2010-07 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00637117 · Baylor Research Institute
2008-07 – 2010-03 · Lymphoma
What this study did
NCT00429416 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2004-03 – 2009-05 · Hematologic Malignancies
What this study did
NCT00030342 · St. Luke's Medical Center
2001-11 – 2008-01 · Colorectal Cancer, Kidney Cancer
What this study did
NCT00022230 · Roger Williams Medical Center
2000-01 – 2007-01 · Breast Cancer
What this study did
NCT00206661 · Genzyme, a Sanofi Company
2004-12 – 2006-12 · Crohn Disease
What this study did
NCT00091052 · Sirius Medicine
2004-07 – 2006-06 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00089219 · University of Virginia
2003-07 – 2006-05 · Intraocular Melanoma, Melanoma (Skin)
What this study did
NCT00002950 · Yale University
1996-09-26 – 2002-02-10 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00004184 · University of Alabama at Birmingham
1998-08 – 2001-06 · Melanoma (Skin)
What this study did
Phase 1 (129)
Acute Myeloid Leukemia
NCT07374029 · David Avigan
2026-02-12 – 2030-10-01 · Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
What this study did
NCT02240537 · Benovus Bio, Inc.
2015-01 – 2017-06 · Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Smoldering Multiple Myeloma (sMM)
What this study did
NCT00012376 · National Cancer Institute (NCI)
2001-03 – 2010-01 · Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Paroxysmal Nocturnal Hemoglobinuria, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Relapsing Chronic Myelogenous Leukemia, Thrombocytopenia, Untreated Adult Acute Myeloid Leukemia
What this study did
NCT00398138 · Memorial Sloan Kettering Cancer Center
2006-10 – 2009-06 · Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes, Primary Peritoneal Cavity Cancer
What this study did
NCT00003003 · Dartmouth-Hitchcock Medical Center
1996-09 – 2000-08 · Leukemia
What this study did
Other / comorbidity
NCT07377435 · David Avigan
2026-01-30 – 2032-03-01 · Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
What this study did
NCT06799026 · David Avigan
2025-01-31 – 2030-09-01 · Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma
What this study did
NCT05544968 · Medical College of Wisconsin
2026-03-04 – 2029-07 · Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma, CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma, CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma, Leukemia, Lymphoma
What this study did
NCT06514898 · University of Florida
2025-05-05 – 2028-12-01 · Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
What this study did
NCT06254326 · University of Florida
2024-09-19 – 2028-06 · Recurrent Oligodendroglioma, Progressive Oligodendroglioma
What this study did
NCT07027748 · Steven DuBois, MD
2025-06-27 – 2027-12-01 · Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma, Refractory Neuroblastoma
What this study did
NCT04270149 · Herbert Lyerly
2020-09-01 – 2027-08-01 · Breast Cancer
What this study did
NCT00669734 · National Cancer Institute (NCI)
2010-02-01 – 2027-04-21 · Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
What this study did
NCT02334865 · Roswell Park Cancer Institute
2017-04-13 – 2026-12-19 · Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma
What this study did
NCT05475106 · Instituto de Medicina Regenerativa
2022-05-12 – 2026-06-20 · Neoplasms
What this study did
NCT02774421 · University of Colorado, Denver
2017-06-12 – 2026-03-31 · Posterior Fossa Ependymoma (PFEPN)
What this study did
NCT05717140 · Mayo Clinic
2025-10-28 – 2026-01-28 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
What this study did
NCT00436254 · University of Washington
2001-10 – 2025-04-01 · HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
What this study did
NCT03396575 · University of Florida
2018-07-17 – 2025-03-20 · Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
What this study did
NCT03334305 · University of Florida
2018-08-27 – 2025-03-20 · Malignant Glioma, High Grade Glioma
What this study did
NCT03879694 · Roswell Park Cancer Institute
2019-06-17 – 2025-03-14 · Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor
What this study did
NCT04040231 · Memorial Sloan Kettering Cancer Center
2019-07-24 – 2024-11-14 · Mesothelioma, Pleural Mesothelioma, Wilms Tumor
What this study did
NCT05677633 · University of Nebraska
2023-01-19 – 2024-11-01 · Parkinson's Disease and Parkinsonism
What this study did
NCT03790670 · University of Nebraska
2019-01-30 – 2024-10-01 · Parkinson Disease
What this study did
NCT03538314 · Ultimovacs ASA
2018-07-09 – 2024-06-15 · Malignant Melanoma
What this study did
NCT03332667 · New Approaches to Neuroblastoma Therapy Consortium
2018-09-12 – 2024-02-23 · Neuroblastoma
What this study did
NCT00487305 · Dana-Farber Cancer Institute
2007-06 – 2023-07-25 · Follicular Lymphoma
What this study did
NCT04408092 · University of Colorado, Denver
2013-06-25 – 2023-07-21 · Ependymoma, Recurrent Childhood, Ependymoma
What this study did
NCT04584112 · Hoffmann-La Roche
2020-09-28 – 2023-03-08 · Triple-Negative Breast Cancer
What this study did
NCT02444546 · Mayo Clinic
2015-06-21 – 2022-11-21 · Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Childhood Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Brain Neoplasm
What this study did
NCT02780401 · University of Washington
2016-09-02 – 2022-10-08 · HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
What this study did
NCT05366283 · Partner Therapeutics, Inc.
2022-04-13 – 2022-06-16 · Drug Kinetics, Drug Effects on Physiology
What this study did
NCT03006146 · Children's Hospital Medical Center, Cincinnati
2017-07-13 – 2021-06-07 · Autoimmune Pulmonary Alveolar Proteinosis
What this study did
NCT03982004 · Washington University School of Medicine
2020-09-14 – 2021-03-03 · Metastatic Breast Cancer
What this study did
NCT02250014 · University of Colorado, Denver
2015-10-05 – 2020-12-21 · Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
What this study did
NCT02411786 · University of Wisconsin, Madison
2015-08-24 – 2020-11-28 · Prostate Cancer
What this study did
NCT03615404 · Gary Archer Ph.D.
2018-10-05 – 2020-07-02 · Glioblastoma, Malignant Glioma, Medulloblastoma Recurrent, Pediatric Glioblastoma Multiforme, Pediatric Brain Tumor, Recurrent, Pediatric Brain Tumor
What this study did
NCT02383212 · Regeneron Pharmaceuticals
2015-02-02 – 2019-11-18 · Advanced Cancer, Advanced Malignancies
What this study did
NCT00383994 · M.D. Anderson Cancer Center
2006-09 – 2019-07-22 · Lymphoma, Leukemia, Transplantation, Stem Cell, Lymphoid Malignancies, Disorder Related to Transplantation
What this study did
NCT02601365 · Milton S. Hershey Medical Center
2019-03 – 2019-05 · Acute Respiratory Distress Syndrome, Pneumonia, Respiratory Virus Infection
What this study did
NCT01061840 · Gradalis, Inc.
2009-12 – 2019-01 · Ewings Sarcoma, Non Small Cell Lung Cancer, Liver Cancer
What this study did
NCT02058680 · OncBioMune Pharmaceuticals
2012-04 – 2018-12 · Prostate Cancer
What this study did
NCT02276300 · Technical University of Munich
2014-12 – 2018-07-13 · Gastric Cancer, Breast Cancer
What this study did
NCT02149225 · Immatics Biotechnologies GmbH
2014-10 – 2018-06 · Glioblastoma
What this study did
NCT00477815 · Mayo Clinic
2005-05-31 – 2018-05-07 · Multiple Myeloma and Plasma Cell Neoplasm
What this study did
NCT00600002 · Edward Nelson
2004-06 – 2018-04 · Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
What this study did
NCT02130869 · St. Jude Children's Research Hospital
2014-10-10 – 2017-12-20 · Neuroblastoma, Lymphoma, High-risk Tumor
What this study did
NCT00834665 · University of Pennsylvania
2006-12 – 2017-12 · Multiple Myeloma
What this study did
NCT02840708 · Niigata University Medical & Dental Hospital
2016-05 – 2017-09-01 · Pulmonary Alveolar Proteinosis, Autoimmune
What this study did
Phase 4 (4)
Other / comorbidity
NCT03769844 · Nationwide Children's Hospital
2018-12-05 – 2023-12-05 · Pediatric Sepsis-induced MODS
What this study did
NCT01495637 · Mark Hall
2011-12 – 2023-02 · Critical Injury (Trauma) in Children
What this study did
NCT04326920 · University Hospital, Ghent
2020-03-24 – 2021-02-26 · COVID-19
What this study did
NCT02451488 · Mayo Clinic
2015-05 – 2016-11-04 · Melanoma
What this study did
Early phase / not applicable (13)
Other / comorbidity
NCT02786719 · Baylor College of Medicine
2016-06 – 2019-02-05 · Neuroblastoma
What this study did
NCT01408901 · Northwestern University
2011-09 – 2017-08-15 · Peripheral Arterial Disease
What this study did
NCT00665002 · H. Lee Moffitt Cancer Center and Research Institute
2008-06 – 2015-02 · Leukemia
What this study did
NCT00673179 · M.D. Anderson Cancer Center
2008-05 – 2010-11 · Osteosarcoma
What this study did
NCT00006243 · National Cancer Institute (NCI)
2000-10 – 2006-05 · Recurrent Melanoma, Stage IV Melanoma
What this study did
NCT00899821 · NYU Langone Health
2000-06 – 2004-12 · Head and Neck Cancer
What this study did
NCT00053157 · Roswell Park Cancer Institute
2002-06 – 2004-08 · Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
What this study did
NCT00000896 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2000-10 · HIV Infections
What this study did
NCT00000989 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 1992-07 · Cytomegalovirus Retinitis, HIV Infections
What this study did
Used as active comparator (7)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Other / comorbidity
NCT01479244 · Galena Biopharma, Inc.
2011-11 – 2016-09-21 · Breast Cancer With Low to Intermediate HER2 Expression
What this study did
NCT01368276 · BioVex Limited
2010-10 – 2014-09 · Melanoma
What this study did
NCT00091676 · Biovest International
2000-01 – 2012-12 · Non-Hodgkins Lymphoma
What this study did
Phase 2 (3)
Other / comorbidity
NCT02636582 · National Cancer Institute (NCI)
2016-06-14 – 2023-05-17 · Breast Ductal Carcinoma In Situ
What this study did
NCT01341652 · University of Wisconsin, Madison
2011-05-23 – 2020-06-30 · Prostate Cancer
What this study did
NCT02978222 · Marker Therapeutics, Inc.
2017-07-20 – 2020-01-15 · Platinum Sensitive Ovarian Cancer, Ovarian Cancer
What this study did
Appears in other studies (4)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Acute Myeloid Leukemia
NCT00046930 · Eastern Cooperative Oncology Group
2002-09-17 – 2009-06 · Leukemia, Myelodysplastic Syndromes
What this study did
NCT00454168 · The Vaccine Company
2005-05 – 2009-04 · Leukemia
What this study did
Phase 2 (2)
Other / comorbidity
NCT05242965 · University of Washington
2023-03-24 – 2032-11-21 · Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT03012100 · Academic and Community Cancer Research United
2017-03-31 – 2026-07-31 · Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unilateral Breast Carcinoma
What this study did

Competitive landscape

This drug's own stage for Acute Myeloid Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sargramostim (Leukine): this drugApprovedProtein / enzyme therapeuticGM-CSF receptornot yet gradedNo reviewed efficacy summary in this indication
Azacitidine (Onureg)ApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)Weak signal
NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results).
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Enasidenib (Idhifa)ApprovedSmall moleculeIDH2Partial signal
NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed
Gemtuzumab OzogamicinApprovedAntibody–drug conjugateCD33Partial signal
NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed
NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients.
GilteritinibApprovedSmall moleculeFLT3Partial signal
NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed
GlasdegibApprovedSmall moleculeHedgehog Pathway InhibitorPartial signalNo reviewed efficacy summary in this indication
Ivosidenib (Tibsovo)ApprovedSmall moleculeMutant IDH1Reliable signal
NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis)
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRWeak signal
NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed
NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results).
OlutasidenibApprovedSmall moleculeMutant IDH1Weak signalFeatured results are safety only in this race
Orca-T (TREGZI)ApprovedCell therapyAllogeneic engineered T-cell immunotherapyPartial signal
NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5)
QuizartinibApprovedSmall moleculeFLT3Reliable signal
NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2)
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Tretinoin (Vesanoid)
ApprovedUS marketing discontinued
Small moleculeRARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLnot yet graded
NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending
VenetoclaxApprovedSmall moleculeBCL-2Reliable signal
NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed
VyxeosApprovedSmall moleculeDNA synthesis (cytarabine, antimetabolite) / Topoisomerase IIPartial signal
NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1).
ZiftomenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
131I-ApamistamabPhase 3Monoclonal antibodyCD45Partial signal
NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001
Arsenic Trioxide (QTX-2101)Phase 3Small moleculePML-RARA fusion oncoproteinnot yet gradedNo reviewed efficacy summary in this indication
Arsenic Trioxide (SDK001)Phase 3Small moleculePML-RARA fusion oncoproteinPartial signalNo reviewed efficacy summary in this indication
AzacitidinePhase 3Small moleculeDNMT1 (DNA methyltransferase 1)Partial signal
NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed
BleximenibPhase 3Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Clifutinib BesylatePhase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
CrenolanibPhase 3Small moleculeFLT3 (including D835/ITD mutants), also PDGFR-alpha/betaReliable signal
NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145)
Galinpepimut-SPhase 3VaccineWT1 (Wilms Tumor-1 protein)Weak signal
NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47%
LisaftoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MocravimodPhase 3Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)not yet gradedNo reviewed efficacy summary in this indication
RuserontinibPhase 3Small moleculeFLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Partial signalNo reviewed efficacy summary in this indication
XY0206Phase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
AnnamycinPhase 2/3Small moleculeTopoisomerase II (TOP2)not yet gradedNo reviewed efficacy summary in this indication
BL-M11D1Phase 2/3Antibody–drug conjugateCD33not yet gradedNo reviewed efficacy summary in this indication
Pivekimab Sunirine (Decnupaz)Phase 2/3Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
CusatuzumabPhase 2Monoclonal antibodyCD70Weak signal
NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38
Lintuzumab-Ac225Phase 2RadiopharmaceuticalCD33Weak signalNo reviewed efficacy summary in this indication
PegargiminasePhase 2Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminaseWeak signal
NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months
PrexigebersenPhase 2RNA / oligonucleotideGRB2 (growth factor receptor-bound protein 2) mRNAWeak signalFeatured results are safety only in this race
RomaciclibPhase 2Small moleculeCDK8 / CDK19Weak signal
NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response
Sonrotoclax (Beqalzi)Phase 2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
TagraxofuspPhase 2Protein / enzyme therapeuticCD123Weak signalNo reviewed efficacy summary in this indication
VididencelPhase 2VaccineAllogeneic dendritic cell vaccineWeak signal
NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported).
AB8939Phase 1/2Small moleculeTubulinnot yet gradedNo reviewed efficacy summary in this indication
ABD-3001Phase 1/2Small moleculeALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)not yet gradedNo reviewed efficacy summary in this indication
AlrizomadlinPhase 1/2Small moleculeMDM2Weak signalNo reviewed efficacy summary in this indication
ARD103Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
AZD3632Phase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BexmarilimabPhase 1/2Monoclonal antibodyClever-1not yet gradedNo reviewed efficacy summary in this indication
BG1805Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
BSB-1001Phase 1/2Cell therapyHA-1 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
CART84Phase 1/2Cell therapyCD84not yet gradedNo reviewed efficacy summary in this indication
CCTx-001Phase 1/2Cell therapyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
CD123 Targeted CAR-NK CellsPhase 1/2Cell therapyCD123Weak signalNo reviewed efficacy summary in this indication
CD123 / CD33 CARTPhase 1/2Cell therapyCD123 / CD33not yet gradedNo reviewed efficacy summary in this indication
CLN-049Phase 1/2Multispecific antibodyFLT3, CD3not yet gradedNo reviewed efficacy summary in this indication
Debio 1562MPhase 1/2Antibody–drug conjugateCD37not yet gradedNo reviewed efficacy summary in this indication
EmavusertibPhase 1/2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
EnzomenibPhase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
LigufalimabPhase 1/2Monoclonal antibodyCD47not yet gradedNo reviewed efficacy summary in this indication
MobinitinibPhase 1/2Small moleculeFLT3 / Aurora kinase A and Bnot yet gradedNo reviewed efficacy summary in this indication
MRX-2843Phase 1/2Small moleculeFlt3/MerTKWeak signalNo reviewed efficacy summary in this indication
OcifisertibPhase 1/2Small moleculePLK4 (Polo-like kinase 4)Weak signalFeatured results are safety only in this race

Large race: only the 60 furthest-along competitors are listed; 70 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(27 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Leukine (Sargramostim) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (1)
Phase 2Alzheimer DiseaseRecruiting
Est. primary completion 2026-11-30 · NCT04902703 · CT.gov ↗
What to watch
December 2026 (3)
Phase 1/2NeuroblastomaActive not recruiting
Est. primary completion 2026-12 · NCT01757626 · CT.gov ↗
What to watch
Phase 1/2Relapsed Neuroblastoma, Refractory NeuroblastomaActive not recruiting
Est. primary completion 2026-12 · NCT04211675 · CT.gov ↗
What to watch
Phase 2Transplant-Related Hematologic MalignancyRecruiting
Est. primary completion 2026-12-31 · NCT04237623 · CT.gov ↗
What to watch
2027 (8)
April 2027 (1)
Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast CarcinomaRecruiting
Est. primary completion 2027-04-30 · NCT07078604 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2NeuroblastomaRecruiting
Est. primary completion 2027-06-15 · NCT04936529 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Recurrent OsteosarcomaActive not recruiting
Est. primary completion 2027-07 · NCT02502786 · CT.gov ↗
What to watch
Phase 1Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma, Refractory NeuroblastomaRecruiting
Est. primary completion 2027-07-01 · NCT07027748 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) MedulloblastomaRecruiting
Est. primary completion 2027-09-01 · NCT06514898 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-10-01 · NCT07374029 · CT.gov ↗
What to watch
December 2027 (2)
Phase 1Recurrent Oligodendroglioma, Progressive OligodendrogliomaRecruiting
Est. primary completion 2027-12 · NCT06254326 · CT.gov ↗
What to watch
Phase 2Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm, Pancreatic Neuroendocrine NeoplasmNot yet recruiting
Est. primary completion 2027-12-15 · NCT06202066 · CT.gov ↗
What to watch
2028 (7)
January 2028 (1)
Phase 1Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma …Recruiting
Est. primary completion 2028-01 · NCT05544968 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Neuroblastoma RecurrentRecruiting
Est. primary completion 2028-02-01 · NCT07085338 · CT.gov ↗
What to watch
March 2028 (2)
Phase 1Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple MyelomaRecruiting
Est. primary completion 2028-03-01 · NCT07377435 · CT.gov ↗
What to watch
Phase 1/2Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2028-03-31 · NCT05269381 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary HypertensionRecruiting
Est. primary completion 2028-08-01 · NCT03630211 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple MyelomaRecruiting
Est. primary completion 2028-09-01 · NCT06799026 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2NeuroblastomaRecruiting
Est. primary completion 2028-12 · NCT06450041 · CT.gov ↗
What to watch
2029 (3)
March 2029 (1)
Phase 2Lung CarcinomaNot yet recruiting
Est. primary completion 2029-03-30 · NCT07169617 · CT.gov ↗
What to watch
July 2029 (1)
Phase 2High-risk Neuroblastoma, Neuroblastoma, Childhood NeuroblastomaRecruiting
Est. primary completion 2029-07-22 · NCT06528496 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1/2Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory NeuroblastomaRecruiting
Est. primary completion 2029-09-30 · NCT07437963 · CT.gov ↗
What to watch
2030 (3)
September 2030 (1)
Phase 3Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, NeuroblastomaRecruiting
Est. primary completion 2030-09-30 · NCT03126916 · CT.gov ↗
What to watch
October 2030 (1)
Phase 1/2Metastatic Uveal MelanomaRecruiting
Est. primary completion 2030-10 · NCT06626516 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Metastatic Hormone Receptor-Negative Breast CarcinomaNot yet recruiting
Est. primary completion 2030-12-31 · NCT07949760 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2031-12 · NCT05232916 · CT.gov ↗
What to watch
2033 (1)
June 2033 (1)
Phase 2/3Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7Active not recruiting
Est. primary completion 2033-06-30 · NCT02339571 · CT.gov ↗
What to watch

See the full readout calendar ↗